2023 begins with FDA decisions for Eisai’s Alzheimer’s project and Pfizer’s zavegepant, with an adcom for Cidara’s rezafungin.
In targeting a genetic cause of the disease, Lexeo reckons it could outdo anti-amyloid antibodies, but has a long way to go.
The failure of Roche’s Graduate 1 and 2 studies can be explained away by insufficient amyloid clearance.
Keenly awaited results reveal no smoking gun, but lecanemab’s modest activity appears not that different from Aduhelm’s.
TG Therapeutics and Gilead also await a verdict, and Cytokinetics is set for a panel.
But the current leader, Vaxxinity, will have to convince its doubters if it is to hook a partner.